Christian Muehlendyck

Christian Muehlendyck

Auto-generated profile, based on publicly available information

Christian Muehlendyck

Johnson & Johnson (Germany), Norderstedt, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CEChristian Eckmann
Christian Eckmann
AKAxel Kramer
Axel Kramer
OAOjan Assadian
Ojan Assadian
SFSteffen Flessa
Steffen Flessa
CHClaudia Huebner
Claudia Huebner
DLDavid John Leaper
David John Leaper
Background: Surgical site infections (SSI) present a substantial burden to patients and healthcare systems. This study aimed to elucidate the prevalence of SSIs in German hospitals and to quantify their clinical and economic burden based on German hospital reimbursement data (G-DRG). Methods: This retrospective, cross-sectional study used a 2010–2016 G-DRG dataset to determine the prevalence of SSIs in hospital, using ICD-10-GM codes, after surgical procedures. The captured economic and clinical outcomes were used to quantify and compare resource use, reimbursement and clinical parameters for patients who had or did not have an SSI. Findings: Of the 4,830,083 patients from 79 hospitals, 221,113 were eligible. The overall SSI prevalence for the study period was 4.9%. After propensity-score matching, procedure type, immunosuppression and BMI ≥30 were found to significantly affect the risk of SSI (p<0.001). Mortality and length of stay (LOS) were significantly higher in patients who had an SSI (mortality: 9.3% compared with 4.5% [p<0.001]; LOS (median [interquartile range, IQR]): 28 [27] days compared with 12 [8] days [p<0.001]). Case costs were significantly higher for the SSI group (median [IQR]) €19,008 [25,162] compared with € 9,040 [7,376] [p<0.001]). A median underfunding of SSI was identified at €1,534 per patient. Interpretation: The dataset offers robust information about the “real-world” clinical and economic burden of SSI in hospitals in Germany. The significantly increased mortality of patients with SSI, and their underfunding, calls for a maximization of efforts to prevent SSI through the use of evidence-based SSI-reduction care bundles.


19 September 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Holger FröhlichHolger Fröhlich
Holger Fröhlich
AHAnne Funck Hansen
Anne Funck Hansen
MHMika Hilvo
Mika Hilvo
GJGunther Jansen
Gunther Jansen
SMSumit Madan
Sumit Madan
CMChristian Muehlendyck
Christian Muehlendyck
The European Health Data Space (EHDS) aspires to enable secure, interoperable, and decentralized health data usage across Europe. This paper explores legal and technical challenges in implementing EHDS goals, particularly for secondary data use. It highlights federated and swarm learning as promising yet complex solutions, requiring robust infrastructure, standardization, and regulatory clarity. We emphasize the need for coordinated legislative and technological advances to realize EHDS ambitions.

1 August 2019 in Medical Devices: Evidence and Research
Verified
Journal Article
Open access
PDF file
BBBernd Brüggenjürgen
Bernd Brüggenjürgen
CMChristian Muehlendyck
Christian Muehlendyck
LGLaura-Valentina Gador
Laura-Valentina Gador
AKAlexander Katzer
Alexander Katzer
Background: Although total knee arthroplasty (TKA) procedures are increasing, patient satisfaction is still inferior compared to total hip arthroplasty. The ATTUNE® Knee System was designed to reduce pain and improve function, leading to greater patient satisfaction and decreased resource utilization in TKA. The objective of this study was to compare length of stay (LOS) of TKA with ATTUNE knee versus LCS® knee implants. Methods: A retrospective chart review analysis in a German center was conducted between 2008 and 2016. All patients without prior ipsilateral knee operation, treated with a cemented LCS or ATTUNE knee were included. Endpoints captured included gender, age, availability of home support, prior contralateral TKA, ASA grade and LOS. Statistical analyses included chi-squared test for differences in patient demographics and Welch two-sample t-test for difference in LOS. Results: Mean LOS in the ATTUNE Knee group (N=85) was 8.3 days (SD: 1.79) compared to 10.4 days (SD: 1.91) in the LCS knee group (N=85). No significant differences in gender, age, availability of home support, prior contralateral TKA, or ASA grade between both cohorts were observed. The 2.1 days reduction was statistically significant (P<0.001; 95%CI: 2.7–1.6). A sensitivity analysis outlined the impact of the study duration: even when assuming that 1.3 days reduction resulted from the observed national LOS decrease, the remaining 0.8 reduction in days LOS reduction was still significant (P<0.01). Conclusion: When comparing two cohorts with similar sociodemographic and medical factors, LOS of ATTUNE knee patients was 2.1 days shorter than patients treated with the LCS knee.

28 November 2025 in JMIR Preprints
Verified
Preprint
Open access
JMJaleh Shoshtarian Malak
Jaleh Shoshtarian Malak
LBLeonie von Berlin
Leonie von Berlin
IBIrina Balaur
Irina Balaur
RHRada Hussein
Rada Hussein
PGPhilip Gribbon
Philip Gribbon
VSVenkata Pardhasaradhi Satagopam
Venkata Pardhasaradhi Satagopam
BACKGROUND Standards for the secondary use of health data are still under development and do not comprehensively address specific categories of health data. Existing health data and interoperability standards are primarily designed for the primary use of healthcare, leaving gaps in their applicability for research, regulatory and decision-making. This research is part of the IDERHA project, which creates a federated processing environment for secondary healthcare use cases aligned with EHDS regulations. OBJECTIVE This study aims to recommend a set of standards and tools to support harmonization objectives in the secondary use of health data. The proposed standards establish a shared representation model for data providers and stakeholders, improving data FAIRness and interoperability. METHODS A comprehensive review and selection of standards and harmonization tools were performed across major health-data categories. Standards from OHDSI/OMOP, HL7 FHIR, DICOM, DCAT-AP/HealthDCAT-AP, GA4GH, INSPIRE, CDISC, and others were evaluated based on community adoption, technical suitability, and alignment with EHDS requirements. Data-harmonization tools were tested in a pilot experiment using synthetic OMOP-CDM based data to assess readiness, quality, and feasibility of applying harmonization workflows within IDERHA. We also assessed the inherent FAIRness of OMOP CDM, identifying its strengths in semantic interoperability and data reuse, while addressing limitations related to metadata discoverability, global identifiers, access control, and licensing through complementary mechanisms implemented in IDERHA. RESULTS In this research, we recommend a set of standards to support the secondary use of heterogeneous health data across clinical, imaging, genomic, socioeconomic, environmental, and PROM/PREM domains. This standards collection, centered on OMOP CDM and complemented by established domain-specific specifications, was paired with selected harmonization and quality-assessment tools from the OHDSI and EHDEN ecosystems. Feasibility testing on synthetic OMOP data confirmed the suitability of tools for evaluating data quality, mapping accuracy, and ETL. A lung-cancer use case demonstrated how diverse datasets can be harmonized and prepared for federated analysis. FAIR-DSM evaluation showed that integrating OMOP data into the IDERHA environment substantially improved FAIRness—particularly in metadata completeness, interoperability, and hosting capabilities—supporting enhanced discoverability, accessibility, and reuse of standardized health data. CONCLUSIONS By strengthening adherence to FAIR principles, this research facilitates the broader integration of standardized health data for regulatory processes and health technology assessment (HTA) applications. The proposed set of standards and tools provides a comprehensive overview of existing approaches, while offering solutions that can be applied to other scenarios involving the secondary use of health data.

22 September 2026 in JMIR Formative Research
Verified
Journal Article
Open access
JMJaleh Shoshtarian Malak
Jaleh Shoshtarian Malak
LBLeonie von Berlin
Leonie von Berlin
IBIrina Balaur
Irina Balaur
RHRada Hussein
Rada Hussein
PGPhilip Gribbon
Philip Gribbon
VSVenkata Pardhasaradhi Satagopam
Venkata Pardhasaradhi Satagopam
Background: Standards for the secondary use of health data remain under development and do not comprehensively address specific categories of health data. Existing health data and interoperability standards are primarily designed for the primary use of health care, leaving gaps in their applicability for research, regulatory and decision-making. This research is part of the Integration of Heterogeneous Data and Evidence Towards Regulatory and Health Technology Assessment Acceptance (IDERHA) project, which creates a federated processing environment for secondary health care use cases. Objective: This study aims to recommend a set of standards and tools to support harmonization objectives in the secondary use of health data. The proposed standards establish a shared representation model for data providers and stakeholders, improving data adherence to findable, accessible, interoperable, and reusable (FAIR) principles and interoperability. Methods: In this exploratory assessment and feasibility study, we performed a consensus-based evaluation of health data standards and harmonization tools across major health-data categories. State-of-the-art standards from different standard-producing organizations were evaluated based on community adoption, technical suitability, and alignment with European Health Data Space requirements. Data-harmonization tools were tested in a pilot experiment using synthetic Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM)–based data to assess the quality and feasibility of applying harmonization workflows within IDERHA. We also assessed the inherent adherence to FAIR principles of the OMOP-CDM, identifying its strengths in semantic interoperability and data reuse. Finally, we addressed the datasets handling challenges (metadata discoverability, global identifiers, access control, and licensing), which are not inherently solvable by bare data description standards, through complementary mechanisms implemented in IDERHA. Results: We recommend a set of standards to support the secondary use of heterogeneous health data across clinical, imaging, genomic, socioeconomic, environmental, and patient-reported outcome measure (PROM)/patient-reported experience measure (PREM) domains. This standards collection, centered on OMOP-CDM and complemented by established extensions, was paired with selected harmonization and quality-assessment tools. Feasibility testing on synthetic OMOP data confirmed the suitability of the tools for evaluating data quality, mapping accuracy, and extract, transform, and load. A lung-cancer use case demonstrated how diverse datasets can be harmonized and prepared for federated analysis. A FAIR-dataset maturity evaluation showed that integrating OMOP data into the IDERHA environment substantially improved adherence to FAIR principles—particularly in metadata completeness, interoperability, and hosting capabilities—supporting enhanced discoverability, accessibility, and reuse of standardized health data. Conclusions: By strengthening adherence to FAIR principles, this research facilitates the broader integration of standardized health data for regulatory processes and health technology assessment applications. The proposed standards and tools provide a comprehensive overview of existing approaches, while offering solutions that can be applied to other scenarios involving the secondary use of health data.